Paxalisib
Glioblastoma (GBM)
Key Facts
About Kazia Therapeutics
Kazia Therapeutics is a Sydney-based, ASX-listed biotech focused on high-unmet-need oncology. Its mission is to identify and develop differentiated drug candidates, primarily through in-licensing, to address cancers with poor prognoses. The company's lead asset, paxalisib, is a PI3K/mTOR inhibitor with Orphan and Fast Track Designation for glioblastoma, representing a potential new treatment paradigm. Kazia's strategy hinges on generating compelling clinical data to enable regulatory approval, strategic partnerships, or acquisition, operating as a capital-efficient, pipeline-focused entity.
View full company profileAbout Kazia Therapeutics
Kazia Therapeutics is a Sydney-based, ASX-listed biotech focused on high-unmet-need oncology. Its mission is to identify and develop differentiated drug candidates, primarily through in-licensing, to address cancers with poor prognoses. The company's lead asset, paxalisib, is a PI3K/mTOR inhibitor with Orphan and Fast Track Designation for glioblastoma, representing a potential new treatment paradigm. Kazia's strategy hinges on generating compelling clinical data to enable regulatory approval, strategic partnerships, or acquisition, operating as a capital-efficient, pipeline-focused entity.
View full company profileAbout Kazia Therapeutics
Kazia Therapeutics is a Sydney-based, ASX-listed biotech focused on high-unmet-need oncology. Its mission is to identify and develop differentiated drug candidates, primarily through in-licensing, to address cancers with poor prognoses. The company's lead asset, paxalisib, is a PI3K/mTOR inhibitor with Orphan and Fast Track Designation for glioblastoma, representing a potential new treatment paradigm. Kazia's strategy hinges on generating compelling clinical data to enable regulatory approval, strategic partnerships, or acquisition, operating as a capital-efficient, pipeline-focused entity.
View full company profileOther Glioblastoma (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| DB102 (Enzastaurin) | Denovo Biopharma | Phase 3 |
| GlioGuard Therapeutic & Diagnostic System | GlioGuard | Pre-clinical |
| DOC1021 | Diakonos Oncology | Phase 2 |
| Lead CAR-T Program | Kiragen Bio | Pre-clinical |
| GBM Immunotherapy (with SandboxAQ) | iOncologi | Pre-clinical |
| DCVax®-L | Northwest Biotherapeutics | Phase 3 |
| Lucicebtide (ST101) | Sapience Therapeutics | Phase 2 |
| Glioblastoma Assay Optimization (CPRIT Grant) | SingleCell Biotechnology | Pre-clinical |
| Lead Program (unspecified) | BlueHaven Therapeutics | Preclinical |
| TLX101 (Pixclara® / 131I-IPA) | Telix Pharmaceuticals | Phase 3 |